Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related … Read more
Xeris Pharmaceuticals Inc (XERS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 1.464x
Based on the latest financial reports, Xeris Pharmaceuticals Inc (XERS) has a cash flow conversion efficiency ratio of 1.464x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($20.04 Million) by net assets ($13.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xeris Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Xeris Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Xeris Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xeris Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shantou Dongfeng Printing Co Ltd
SHG:601515
|
-0.004x |
|
Advanced Energy Solution Holding Co. Ltd
TW:6781
|
0.026x |
|
Monde Nissin Corporation
PINK:MNDDF
|
0.073x |
|
Jungfraubahn Holding AG
OTCGREY:JFBHF
|
0.037x |
|
Beijing Fuxing Xiaocheng Electronic Technology Co Ltd
SHE:300139
|
0.006x |
|
Predictive Discovery Ltd
AU:PDI
|
-0.030x |
|
Nanjing Hongbaoli Corp Ltd
SHE:002165
|
-0.026x |
|
TPV Technology Co Ltd
SHE:000727
|
-0.186x |
Annual Cash Flow Conversion Efficiency for Xeris Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Xeris Pharmaceuticals Inc from 2016 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.69 Million | $28.63 Million | 2.091x | +67.46% |
| 2024-12-31 | $-29.61 Million | $-36.98 Million | 1.249x | -81.99% |
| 2023-12-31 | $-6.78 Million | $-47.02 Million | 6.934x | +404.50% |
| 2022-12-31 | $45.19 Million | $-102.89 Million | -2.277x | -126.98% |
| 2021-12-31 | $95.23 Million | $-95.53 Million | -1.003x | +82.02% |
| 2020-12-31 | $14.44 Million | $-80.56 Million | -5.580x | +22.80% |
| 2019-12-31 | $14.44 Million | $-104.35 Million | -7.228x | -868.48% |
| 2018-12-31 | $75.41 Million | $-56.28 Million | -0.746x | -275.00% |
| 2017-12-31 | $-57.83 Million | $-24.66 Million | 0.426x | -15.34% |
| 2016-12-31 | $-31.93 Million | $-16.09 Million | 0.504x | -- |